Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Robo Global Robotics & Automation ETF (ROBO) vs Viatris Inc (VTRS) Price & Performance

Global X Robo Global Robotics & Automation ETFTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Global X Robo Global Robotics & Automation ETF vs Viatris Inc — how do they compare? Global X Robo Global Robotics & Automation ETF trades at $81.23 (market cap $2.06B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 9.7× Global X Robo Global Robotics & Automation ETF's market cap, and Viatris Inc pays a 2.75% dividend while Global X Robo Global Robotics & Automation ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Robo Global Robotics & Automation ETF for 36 Days and Viatris Inc for 57 Days on average.

ROBOVTRS
Market Cap
$2.06B$20.03B
Volume
148,11114,109,977
Sector
Sector/ThematicHealth
52-Week High
$90.34$18.27
52-Week Low
$63.04$9.74
Typical Hold Time
36 Days57 Days
Enterprise Value
—$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Robo Global Robotics & Automation ETF

ROBO trades at $81.82, down 1.89% today amid mixed technical signals. The overall technical outlook remains bullish with strong moving average support, though oscillators show bearish momentum with RSI levels above 79 indicating potential overbought conditions. Recent news highlights accelerating robotics adoption across manufacturing, healthcare, and military applications, with Q2 2026 earnings showing broadening demand for physical AI technologies.

The robotics ETF offers diversified exposure to a sector benefiting from labor shortages and AI infrastructure growth. Key risks include valuation concerns amid rapid sector expansion and potential market volatility. Analyst coverage remains positive on long-term robotics adoption trends, though current technical indicators suggest near-term consolidation may be needed after recent gains.

Viatris Inc

Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.

The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

ROBO
100% Buy0% Sell
Avg holding period · 36 Days
VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About Global X Robo Global Robotics & Automation ETF

ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.

Read more on ROBO →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →